| Title： | Expert consensus on pharmaceutical practice of fondaparinux sodium |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | Medicine and clinical pharmacy |
| Evidence classification method： | GRADE classification system |
| Development unit： | 中华医学会临床药学分会；四川省医学科学院&四川省人民医院 |
| Registration time: | 2022-11-19 |
| Registration number： | PREPARE-2022CN750 |
| Purpose of the guideline: | Thromboembolic disease is a kind of disease with high mortality and serious harm to human health. Anticoagulant therapy is the main treatment for thromboembolic disease. As a parenteral anticoagulant, fondaparinux sodium has caused many problems for medical workers due to the differences in indications at home and abroad and the lack of understanding of its application. There are irrational drug use and drug use beyond the instructions in clinical practice. Therefore, it is particularly important to strengthen the rational use of fondaparinux sodium. |
